Table III.

Association of HbA1c and FBG with other variables.

Dependent variable	R2	ANOVA	Model	B	β	t-value	P-valuea
Log [HbA1c (%)]	0.48	F=12.95, P<0.01	Constant	0.86	–	13.24	<0.01
			Age	<-0.01	−0.06	−1.03	0.30
			Log (duration of DM)	0.02	0.08	1.47	0.14
			Log [FBG (mmol/l)]	0.29	0.54	10.53	<0.01
			Log [25-hydroxy- vitamin D (ng/ml)]	−0.05	−0.13	−2.67	<0.01
			Type of DM	−0.06	−0.17	−2.39	0.02
			Sex	−0.02	−0.09	−1.64	0.10
			Smoking	0.01	0.03	0.56	0.57
			Metformin therapy	−0.03	−0.07	−1.17	0.24
			Sulfonylureas therapy	0.01	0.03	0.56	0.58
			Insulin therapy	<0.01	<0.01	0.15	0.88
			Statin therapy	<0.01	0.04	0.70	0.49
			Beta blocker therapy	0.02	0.06	1.15	0.25
			ACEIs therapy	0.02	0.07	1.18	0.24
			Aspirin therapy	−0.02	−0.11	−1.81	0.07
			CCBs therapy	<-0.01	−0.01	−0.27	0.79
			PPIs therapy	−0.01	−0.05	−1.06	0.29
Log [FBG (mmol/l)]	0.42	F=11.00, P<0.01	Constant	−0.15	–	−0.86	0.39
			Log (duration of DM)	0.03	0.07	1.29	0.20
			Log [HbA1c (%)]	1.14	0.61	10.69	<0.01
			Log [25-hydroxy-vitamin D (ng/ml)]	−0.02	−0.04	−0.68	0.50
			Type of DM	−0.02	−0.03	−0.41	0.68
			Sex	<0.01	0.02	0.27	0.79
			Smoking	<0.01	<0.01	0.13	0.90
			Metformin therapy	0.09	0.13	2.01	0.05
			Sulfonylureas therapy	0.02	0.06	1.02	0.31
			Insulin therapy	−0.02	−0.05	−0.88	0.38
			Statins therapy	−0.05	−0.12	−2.02	0.04
			Beta blocker therapy	−0.01	−0.02	−0.33	0.74
			ACEIs therapy	−0.03	−0.06	−1.07	0.29
			Aspirin therapy	0.04	0.11	1.75	0.08
			CCBs therapy	<0.01	0.01	0.24	0.81
			PPIs therapy	0.03	0.06	1.03	0.30

^aMultiple linear regression analysis (P-values were considered statistically significant at <0.05). HbA1c, hemoglobin A1c; DM, diabetes mellitus; FBG, fasting blood glucose; ACEIs, angiotensin converting enzyme inhibitors; CCBs, calcium channel blockers; PPIs, proton pump inhibitors; R2, coefficient of determination; B, unstandardized coefficient; β, standardized coefficient; F, F-statistic; t, t-statistic.